BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/24/2022 9:00:23 AM | Browse: 515 | Download: 1334
 |
Received |
|
2022-01-13 04:18 |
|
Peer-Review Started |
|
2022-01-13 04:20 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-03-09 02:54 |
|
Revised |
|
2022-03-11 09:04 |
|
Second Decision |
|
2022-05-07 07:56 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-05-08 07:06 |
|
Articles in Press |
|
2022-05-08 07:06 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-06-15 02:34 |
|
Publish the Manuscript Online |
|
2022-06-24 09:00 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Jun-Hyung Cho and So-Young Jin |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Soonchunhyang University Research Fund |
10210061 |
|
| Corresponding Author |
Jun-Hyung Cho, MD, PhD, Associate Professor, Digestive Disease Center, Soonchunhyang University Hospital, 59, Daesagwan-ro, Yongsan-gu, Seoul 04401, South Korea. chojhmd@naver.com |
| Key Words |
Helicobacter pylori; Treatment; Antibiotic resistance; China; Japan; South Korea |
| Core Tip |
Since 2000, the standard triple regimen containing clarithromycin (CAM) has been used as a legacy therapy to eradicate Helicobacter pylori (H. pylori). Resistance to CAM by H. pylori has increased to > 15% in East Asia. First-line eradication rates below 80% are strongly associated with CAM-resistant H. pylori strain emergence. H. pylori treatment guidelines in China, Japan, and South Korea were revised according to new data. In China, adding bismuth to H. pylori regimens was recommended as an empirical first-line treatment. In Japan, H. pylori treatment success increased when the potassium-competitive acid blocker (P-CAB) was introduced. In South Korea, tailored H. pylori eradication based on molecular testing for CAM resistance is used as the first-line treatment option. Dual therapy involving frequent administration of high-dose amoxicillin has shown good efficacy for H. pylori eradication in clinical trials. Furthermore, P-CABs, with their rapid and strong acid-suppressing activity, may contribute to successful H. pylori treatment in future. |
| Publish Date |
2022-06-24 09:00 |
| Citation |
Cho JH, Jin SY. Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea. World J Clin Cases 2022; 10(19): 6349-6359 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i19/6349.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i19.6349 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
